July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Change in 1-year visual acuity gain with age-related macular degeneration from 2006 and 2015
Author Affiliations & Notes
  • Sachi Nishino
    Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
  • Tsutomu Yasukawa
    Ophthalmology, Nagoya City University, Japan
  • Hiroko Imaizumi
    Ophthalmology, Sapporo City General Hospital, Japan
  • Hisashi Mastubara
    Ophthalmology, Mie University, Japan
  • Hiroto Ishikawa
    Ophthalmology, Hyogo College of Medicine, Japan
  • Kazuhiro Kimura
    Ophthalmology, Yamaguchi University, Japan
  • Hiroto Terasaki
    Ophthalmology, Kagoshima University, Japan
  • Yoshinori Mitamura
    Ophthalmology, Tokushima University, Japan
  • Toshinori Murata
    Ophthalmology, Shinshu University, Japan
  • Mariko Yamashita
    Ophthalmology, Nara Medical University, Japan
  • Jiro Kogo
    Ophthalmology, St. Marianna University School of Medicine, Japan
  • Masaru Takeuchi
    Ophthalmology, National Defense Medical College, Japan
  • Yoshihiro Takamura
    Ophthalmology, University of Fukui, Japan
  • Tomoya Murakami
    Ophthalmology, University of Tsukuba, Japan
  • Taiji Sakamoto
    Ophthalmology, Kagoshima University, Japan
  • Masahito Ohji
    Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
  • Footnotes
    Commercial Relationships   Sachi Nishino, None; Tsutomu Yasukawa, Alcon Japan (R), Alcon Pharma (F), Alcon Pharma (R), AMO Japan (R), Baseconnect Inc. (R), Bausch & Lomb Japan (R), Bayer (R), CRESCO (R), HOYA (F), HOYA (R), NIDEK (F), NIKKEN SOHONSHA (R), Nitten (R), Novartis Pharma (R), ONO PHARMACEUTICAL (R), Pfizer (R), Santen (R), SANWA KAGAKU KENKYUSHO (R), Senju (R); Hiroko Imaizumi, None; Hisashi Mastubara, Bayer (R), Novartis Pharma (F), Novartis Pharma (R), Santen (R), Senju (R); Hiroto Ishikawa, Alcon (F), AMO (R), Santen (R); Kazuhiro Kimura, Bayer (R), Novartis Pharma (R), Pfizer (R), Santen (R); Hiroto Terasaki, Alcon Pharma (F), Alcon Pharma (R), Bayer (R), JFC Sales Plan (R), Santen (R); Yoshinori Mitamura, Alcon Japan (F), AMO Japan (F), Pfizer (F), Santen (F); Toshinori Murata, Alcon Pharma (F), Bayer (F); Mariko Yamashita, None; Jiro Kogo, None; Masaru Takeuchi, None; Yoshihiro Takamura, None; Tomoya Murakami, None; Taiji Sakamoto, Alcon Japan (R), Alcon Japan (F), Bayer (R), Bayer (F), Graybug (R), Novartis Pharma (R), Novartis Pharma (F), Novartis Pharma (C), Santen (R), Santen (F), Santen (C), Senju (R), Senju (F), Senju (C), TOPCON (P); Masahito Ohji, Alcon Japan (F), Alcon Japan (R), Allergan (C), Baseconnect Inc. (R), Bayer (R), Bayer (C), HOYA (F), HOYA (C), Kowa (R), Novartis Pharma (F), Novartis Pharma (R), Novartis Pharma (C), Otsuka Pharmaceutical Co. (F), Otsuka Pharmaceutical Co. (R), Pfizer (F), Pfizer (R), R.E.MEDICAL (R), Santen (F), Santen (R), Santen (C), Senju (F), Senju (R), TOPCON (R), ZEISS (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 92. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sachi Nishino, Tsutomu Yasukawa, Hiroko Imaizumi, Hisashi Mastubara, Hiroto Ishikawa, Kazuhiro Kimura, Hiroto Terasaki, Yoshinori Mitamura, Toshinori Murata, Mariko Yamashita, Jiro Kogo, Masaru Takeuchi, Yoshihiro Takamura, Tomoya Murakami, Taiji Sakamoto, Masahito Ohji; Change in 1-year visual acuity gain with age-related macular degeneration from 2006 and 2015. Invest. Ophthalmol. Vis. Sci. 2019;60(9):92.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To investigate 1-year change of visual acuity (VA) in eyes with neovascular age-related macular degeneration (AMD) from 2006 and 2015.

Methods : Retrospective and multicenter review of patients with treatment-naïve neovascular AMD who initiated treatment with either photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF) (pagaptanib, ranibizumab or aflibercept) or PDT with anti-VEGF from 2006 to 2015. The best-corrected visual acuity (BCVA) was converted to the logarithm of the minimum angle of resolution (logMAR) VA. The difference between baseline and 1-year VA was evaluated using Wilcoxon matched-pairs signed rank test.

Results : 3,033 eyes of 2,858 patients were included. Mean age was 73.6 ± 8.6 years. Mean BCVA in logMAR at baseline and 1-year after treatment was 0.75 ± 0.44 and 0.70 ± 0.51 (n=141) in 2006, 0.74± 0.44 and 0.69 ± 0.50 (n=146) in 2007, 0.63 ± 0.39 and 0.61 ± 0.47 (n=116) in 2008, 0.58 ± 0.43 and 0.54 ± 0.51 (n=234) in 2009, 0.54 ± 0.44 and 0.49 ± 0.48 (n=354) in 2010, 0.48 ± 0.42 and 0.47 ± 0.51 (n=364) in 2011, 0.52 ± 0.44 and 0.43 ± 0.45 (n=400) in 2012, 0.46 ± 0.41 and 0.37 ± 0.44 (n=434) in 2013, 0.45 ± 0.41 and 0.33 ± 0.39 (n=381) in 2014, and 0.43 ± 0.41 and 0.37 ± 0.44 (n=463) in 2015. BCVA of 1-year after treatment did not have significant difference compared with baseline BCVA in 2006, 2007, and 2008, respectively. BCVA of 1-year after treatment improved significantly compared with the baseline BCVA of eyes treated in 2009 (p < 0.01), 2010 (p < 0.01), 2011 (p < 0.05), 2012 (p < 0.0001), 2013 (p < 0.0001), 2014 (p < 0.0001), 2015 (p < 0.0001), respectively.

Conclusions : The BCVA of 1-year after treatment compared to baseline BCVA has improved significantly in AMD eyes treated during each years through 2009 to 2015.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.